Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

Starting soon

Conditions studied: Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)

In brief

PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart. Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.

Key facts

Study ID

NCT07147751

Run by

International Extranodal Lymphoma Study Group (IELSG)

People needed

100

Starts

2026-09-01

Expected to finish

2029-12-01

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.
• Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.
• Availability of the baseline and follow-up annotations

You may not qualify if…

• Established immunodeficiency conditions.
• Secondary CNS localizations of DLBCL
• Transformed DLBCL

Where it is running

• Fondazione IRCCS Policlinico San Matteo Pavia — Pavia, Italy
• Oncology Institute of Southern Switzerland and Institute of Oncology Research — Bellinzona, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.